NFA
FBRX icon

Nationwide Fund Advisors’s Forte Biosciences FBRX Stock Holding History

Nationwide Fund Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13
Closed -$59K – 706
2017
Q3 		$59K Hold
13
– – ﹤0.01% 3017
2017
Q2 		$57K Buy
+13
New +$73.1K ﹤0.01% 3043

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nationwide Fund Advisors's FBRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Forte Biosciences (FBRX) in Q4 2017, closing a stake of 13 shares — an estimated $59K sold.

Nationwide Fund Advisors first reported a position in FBRX in Q2 2017 and held it in 2 quarters. The position peaked at $59K in Q3 2017. 57 funds tracked by Wall St. Rank hold FBRX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Forte Biosciences position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 13 Forte Biosciences shares in Q4 2017, an estimated $59K.
  • Nationwide Fund Advisors first reported a position in Forte Biosciences in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Forte Biosciences position peaked at $59K in Q3 2017.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.